Amlodipine Pharmacokinetics (ADME)

How Amlodipine Works: Mechanism of Action

Amlodipine selectively blocks L-type voltage-gated calcium channels in vascular smooth muscle and, to a lesser degree, cardiac myocytes. By preventing calcium influx during depolarization, the drug reduces intracellular calcium concentrations, which relaxes arterial smooth muscle and lowers peripheral vascular resistance [1]. This vasodilation reduces afterload on the left ventricle and decreases systemic blood pressure.

The selectivity of amlodipine for vascular over cardiac tissue distinguishes it from non-dihydropyridine calcium channel blockers such as verapamil and diltiazem. At therapeutic concentrations, amlodipine produces minimal negative inotropic or chronotropic effects [2]. The slow onset of vasodilation (peak effect at 6-12 hours) avoids the baroreceptor-mediated reflex tachycardia that plagued first-generation dihydropyridines like immediate-release nifedipine.

In coronary arteries, amlodipine dilates both large epicardial vessels and arterioles, improving myocardial oxygen delivery. This dual vascular action explains its efficacy in both hypertension and chronic stable angina [1]. The ASCOT-BPLA trial (N=19,257) demonstrated that an amlodipine-based regimen reduced all-cause mortality by 11% and cardiovascular events by 16% compared to an atenolol-based regimen over a median 5.5-year follow-up, leading to early termination of the trial [3].

Absorption

Oral absorption of amlodipine is slow and nearly complete. After a single 5 mg or 10 mg dose, peak plasma concentrations occur between 6 and 12 hours [1]. This gradual absorption profile is a direct consequence of the drug's physicochemical properties: amlodipine is a weak base (pKa 8.6) that becomes protonated at physiological pH, which slows its transit across gastrointestinal membranes [4].

Absolute bioavailability ranges from 64% to 90% across published studies [1][2]. Food does not alter the rate or extent of absorption to a clinically meaningful degree, so the drug can be taken without regard to meals. The FDA-approved label cites a mean bioavailability of approximately 64%, while independent pharmacokinetic analyses using more sensitive assays have reported values closer to 80-90% [4].

The slow absorption is clinically advantageous. It produces a flat plasma concentration-time curve with a low peak-to-trough ratio. That ratio (approximately 1.5:1 at steady state) is among the lowest of any antihypertensive, which explains why amlodipine maintains blood pressure control even when a dose is taken 2-3 hours late [2].

Distribution

Amlodipine distributes extensively into tissues. The apparent volume of distribution is approximately 21 L/kg, indicating that the drug partitions heavily out of the plasma compartment and into peripheral tissues, particularly vascular smooth muscle cell membranes [1][4].

Plasma protein binding sits at approximately 97.5%, primarily to albumin [1]. This high protein binding means that only about 2.5% of circulating drug is pharmacologically active at any moment. Conditions that reduce serum albumin (nephrotic syndrome, advanced cirrhosis, critical illness) could theoretically increase the free fraction, though clinically significant changes have not been well-documented for amlodipine specifically.

The large volume of distribution is a key determinant of the long half-life. Amlodipine partitions into lipid bilayers of cell membranes, creating a tissue reservoir that releases drug slowly back into plasma [4]. Researchers at the University of Cambridge described this as a "membrane depot" effect. The drug intercalates into the lipid bilayer near the calcium channel and remains associated with the membrane long after plasma concentrations have declined. This interaction between the drug's dihydropyridine ring and the membrane phospholipids explains why amlodipine's duration of action exceeds what its plasma half-life alone would predict.

Hemodialysis does not significantly remove amlodipine from the body due to this extensive tissue binding and high protein binding [1]. Patients on dialysis do not require supplemental dosing after sessions.

Metabolism

The liver is the primary site of amlodipine biotransformation. CYP3A4 is the dominant enzyme responsible for converting amlodipine to inactive pyridine metabolites through oxidative cleavage of the dihydropyridine ring [1][5]. Unlike some other CYP3A4 substrates, amlodipine does not undergo significant first-pass metabolism, which contributes to its high oral bioavailability.

Approximately 90% of absorbed amlodipine is converted to inactive metabolites [1]. None of the identified metabolites possess clinically relevant pharmacological activity. This is a practical advantage: unlike with some antihypertensives, clinicians do not need to account for active metabolites when predicting drug effect duration or intensity.

CYP3A4 inhibitors can raise amlodipine exposure. Coadministration with diltiazem (itself a moderate CYP3A4 inhibitor) increased amlodipine AUC by 57% in a pharmacokinetic study of 43 elderly hypertensive patients [6]. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, and clarithromycin are expected to produce similar or greater increases in amlodipine plasma concentrations, though large dedicated interaction studies are limited. The FDA label recommends monitoring for hypotension and edema when CYP3A4 inhibitors are combined with amlodipine [1].

CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) may reduce amlodipine exposure and blunt its antihypertensive effect. A study in healthy volunteers showed that rifampin 600 mg daily reduced amlodipine AUC by approximately 40% [7]. In patients requiring both drugs, blood pressure should be monitored closely and amlodipine dose adjusted as needed.

Amlodipine does not significantly inhibit or induce CYP enzymes at therapeutic concentrations [1]. This makes it a relatively "clean" drug from a drug-interaction standpoint, with the major concern being its own susceptibility to CYP3A4 modulation rather than its effect on other medications.

Elimination

The terminal elimination half-life of amlodipine is 30 to 50 hours in healthy adults, with most estimates centering around 35-40 hours [1][2]. This prolonged half-life is the pharmacokinetic foundation for once-daily dosing. Steady-state plasma concentrations are reached after 7 to 8 consecutive daily doses [1].

Renal excretion accounts for approximately 60% of the administered dose (primarily as inactive metabolites) and roughly 10% as unchanged parent drug [1]. The remainder is eliminated in feces. Because the kidneys handle metabolites rather than active drug, renal impairment does not significantly alter the pharmacokinetics of amlodipine. Patients with severe renal impairment (creatinine clearance <10 mL/min) show no meaningful change in amlodipine plasma concentrations, and dose adjustment is not required [1][8].

The Endocrine Society and FDA labeling both note that changes in amlodipine plasma concentrations do not correlate with the degree of renal impairment [1]. This renal "forgiveness" is a practical consideration when selecting an antihypertensive for patients with chronic kidney disease.

Total plasma clearance of amlodipine is approximately 7 mL/min/kg (about 0.42 L/hr/kg), which is low relative to hepatic blood flow [4]. This low clearance, combined with the large volume of distribution, mathematically determines the long half-life (half-life = 0.693 × Vd / clearance).

Special Populations: Elderly Patients

Aging alters amlodipine pharmacokinetics in clinically relevant ways. In patients older than 65, the AUC increases by approximately 40-60% and the elimination half-life extends to 40-65 hours compared to younger adults [1][9]. Peak plasma concentrations are also higher.

These changes reflect age-related declines in hepatic blood flow and CYP3A4 activity. The FDA label recommends initiating therapy at 2.5 mg daily in elderly patients, a starting dose half that of the standard 5 mg [1]. The ACC/AHA 2017 hypertension guidelines identify calcium channel blockers, including amlodipine, as a preferred first-line class for older adults, but emphasize the importance of low starting doses [10].

Elderly patients are more susceptible to amlodipine-associated peripheral edema. The higher drug exposure in this population contributes to the increased incidence. In ALLHAT (N=33,357), peripheral edema occurred in approximately 15% of patients on amlodipine, with higher rates in older subgroups [11].

Special Populations: Hepatic Impairment

Hepatic impairment substantially affects amlodipine pharmacokinetics. Because CYP3A4-mediated metabolism is the primary elimination pathway, reduced hepatic function prolongs both the half-life and the time to reach steady state [1].

In patients with moderate to severe hepatic impairment (Child-Pugh B or C), the elimination half-life extends to approximately 60 hours, and peak plasma concentrations are reached later [1][12]. The AUC increases by roughly 40-60% compared to patients with normal liver function. The FDA label recommends a starting dose of 2.5 mg in patients with hepatic impairment, with careful upward titration as tolerated [1].

No formal pharmacokinetic studies have established dose adjustment guidelines for specific Child-Pugh classes. The 2.5 mg starting dose recommendation applies broadly to all patients with clinically apparent liver disease. Blood pressure monitoring and assessment for dose-dependent adverse effects (ankle edema, dizziness, flushing) should guide titration.

Chirality and the S-Amlodipine Question

Amlodipine besylate is marketed as a racemic mixture of R-(+) and S-(-) enantiomers. The pharmacological activity resides almost entirely in the S-enantiomer, which binds the L-type calcium channel with approximately 1,000-fold greater affinity than R-amlodipine [13].

S-amlodipine (levamlodipine) is marketed in some countries as a standalone product at half the racemic dose (2.5 mg S-amlodipine ≈ 5 mg racemic amlodipine). The theoretical advantage is a lower total drug load with fewer dose-dependent side effects, particularly peripheral edema. A meta-analysis of 12 randomized trials (N=2,849) found that S-amlodipine 2.5 mg produced comparable blood pressure reduction to racemic amlodipine 5 mg, with a statistically significant reduction in ankle edema (RR 0.52, 95% CI 0.38-0.71) [14].

The two enantiomers also differ in their pharmacokinetics. S-amlodipine has a slightly longer half-life (40-50 hours) than R-amlodipine (30-40 hours) [13]. At steady state with racemic dosing, the S-enantiomer accounts for roughly 60% of total plasma amlodipine. This enantiomeric enrichment over time means the pharmacologically active species accumulates preferentially, which may contribute to the observation that amlodipine's antihypertensive effect strengthens slightly over the first 1-2 weeks of therapy.

Clinical Implications of the Pharmacokinetic Profile

The pharmacokinetic properties of amlodipine translate directly into clinical advantages that have made it one of the most prescribed antihypertensives worldwide, with over 80 million prescriptions dispensed annually in the United States [15].

Forgiveness for missed doses. The 30-50 hour half-life means that a single missed dose produces only a modest decline in plasma concentration. Blood pressure control is maintained for at least 24 hours beyond a missed dose in most patients [2]. This pharmacokinetic "forgiveness" is a real-world advantage given that antihypertensive adherence rates average only 50-70% at one year.

Smooth 24-hour control. The low peak-to-trough ratio (approximately 1.5:1) produces consistent blood pressure reduction throughout the dosing interval, including the early morning hours when cardiovascular event risk is highest [2]. Ambulatory blood pressure monitoring studies confirm that amlodipine maintains a trough-to-peak ratio exceeding 80%, well above the FDA-recommended minimum of 50% [1].

Predictable steady-state. Reaching steady state in 7-8 days means clinicians should wait at least one week, and ideally two, before assessing the full effect of a dose change. Premature titration within the first few days risks overshoot and hypotension once accumulation is complete.

Combination therapy flexibility. The absence of significant CYP enzyme inhibition allows safe coadministration with ACE inhibitors, ARBs, thiazide diuretics, and statins. The ASCOT-BPLA trial validated the amlodipine-perindopril combination as superior to atenolol-bendroflumethiazide for preventing cardiovascular events [3]. Fixed-dose combinations of amlodipine with benazepril, olmesartan, valsartan, and atorvastatin are commercially available and supported by pharmacokinetic compatibility data.

Starting dose for most adults is 5 mg once daily, titrated to 10 mg based on blood pressure response after 7-14 days; for elderly patients and those with hepatic impairment, begin at 2.5 mg once daily [1].